ABVC BioPharma, Inc. (ABVC)
0.8701
-0.04
(-4.43%)
USD |
NASDAQ |
Nov 19, 15:45
ABVC BioPharma Debt to Equity Ratio : 0.3057 for Sept. 30, 2026
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| September 30, 2026 | 0.3057 |
| June 30, 2026 | 0.2807 |
| March 31, 2026 | 0.2535 |
| December 31, 2025 | 0.322 |
| September 30, 2025 | 0.2179 |
| June 30, 2025 | 0.3299 |
| March 31, 2025 | 0.5532 |
| December 31, 2024 | 2.613 |
| September 30, 2024 | 0.3285 |
| June 30, 2024 | 0.33 |
| March 31, 2024 | 0.3384 |
| December 31, 2023 | 1.781 |
| September 30, 2023 | 0.3975 |
| June 30, 2023 | 11.77 |
| March 31, 2023 | 2.222 |
| December 31, 2022 | 0.7669 |
| September 30, 2022 | 0.475 |
| June 30, 2022 | 0.2989 |
| March 31, 2022 | 0.3636 |
| September 30, 2021 | 0.3245 |
| June 30, 2021 | 1.574 |
| March 31, 2021 | 1.196 |
| December 31, 2020 | 1.026 |
| September 30, 2020 | 1.716 |
| June 30, 2020 | 1.912 |
| Date | Value |
|---|---|
| March 31, 2020 | 1.937 |
| December 31, 2019 | 1.271 |
| September 30, 2019 | 0.8455 |
| June 30, 2019 | -2.313 |
| March 31, 2019 | -1.012 |
| December 31, 2018 | -1.769 |
| September 30, 2018 | -1.875 |
| June 30, 2018 | -2.042 |
| March 31, 2018 | -2.217 |
| December 31, 2017 | -0.6318 |
| September 30, 2017 | 0.00 |
| June 30, 2017 | 0.00 |
| December 31, 2016 | 0.00 |
| September 30, 2016 | 0.00 |
| June 30, 2016 | -0.242 |
| March 31, 2016 | 0.00 |
| December 31, 2015 | 0.00 |
| September 30, 2015 | 0.5498 |
| June 30, 2015 | 0.5351 |
| March 31, 2015 | 0.5096 |
| December 31, 2014 | 0.5424 |
| September 30, 2014 | 0.5229 |
| June 30, 2014 | 0.00 |
| March 31, 2014 | 0.00 |
| December 31, 2013 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| T2 Biosystems, Inc. | -- |
| Anika Therapeutics, Inc. | 0.1901 |
| Perspective Therapeutics, Inc. | 0.0125 |
| MiMedx Group, Inc. | 0.00 |
| Abbott Laboratories | 0.6106 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 20.30M |
| Total Liabilities (Quarterly) | 8.554M |
| Shareholders Equity (Quarterly) | 13.05M |
| Current Ratio | 0.1953 |
| Net Debt Paydown Yield | -1.18% |